Healtcare PD-1 and PDL-1 Inhibitors Market | Page 2

•Applications
•Non-small cell lung cancer
•Kidney cancer
•Melanoma of the skin
•Bladder cancer
•Merkel cell skin cancer
•Others
For More Information @ https://www.coherentmarketinsights.com/ongoing-insight/pd-1-and-
pdl-1-inhibitors-market-173
PD-1 inhibitors are effective in treating non-small-cell lung carcinoma (NSCLC), kidney cancer,
melanoma of the skin, head and neck cancers, bladder cancer, and Hodgkin lymphoma. Opdivo is
leading the race with US$ 3.8 Bn in sales in 2016, compared to US$ 1.4 Bn of Keytruda in 2016.
Both these drugs have garnered significant development in past two years with respect to extended
therapeutic application and approvals in European countries and Japan.
PDL-1 inhibitors are proven to be effective in NSCLC, bladder cancer, and Merkel cell skin cancer.
Avelumab received FDA approval in March 2017 for metastatic Merkel cell carcinoma (MCC), a
rare skin cancer with no approved therapies. The drug therefore, received approval under the
accelerated approval process, requiring the developers, Pfizer, Inc. and Merck KGaA to conduct
larger clinical trials to establish complete safety and efficacy of the drug. The drug is also being
tested for bladder cancer, NSCLC, gastric cancer, ovarian cancer, and renal cancer, under the
JAVELIN clinical trial program. Extended therapeutic applications widens the potential opportunity
for the drugs in the global PD-1 inhibitors and PDL-1 inhibitors market.
Active research activities to spur the global PD-1 and PDL-1 inhibitors market growth
PD-1 and PDL-1 biomarkers are also called immune checkpoints. Trails from Merck & Co. and
Bristol-Myers Squibb have shown PD-1 and PDL-1 inhibitors to be effective in patients expressing
higher level of PD-1 and PDL-1 biomarkers, restricting the potential market to only these patients.
Therefore, all of the big pharma companies in the global market of PD-1 and PDL-1 inhibitors are
combining the PD-1 and PDL-1 inhibitors with other targeted cancer drugs to cater to a larger set of
population. The global PD-1 and PDL-1 inhibitors market is poised to grow significantly with more
product developments in the segment. There are 65 clinical studies in phase 2 and phase 3 phase
globally. Commercialization of a novel drug in this segment would be a great booster for the growth
for the PD-1 and PDL-1 inhibitors market.
Regional PD-1 and PDL-1 inhibitors market outlook
A major share of the revenue of the global PD-1 and PDL-1 inhibitors market is currently
concentrated in North America, Europe, and Japan as these are the three major revenue generating
nations with high insurance coverage, high healthcare investment, and are highly developed
pharmaceutical markets. The market players would be eyeing other regions for tapping the cancer
treatment market opportunities in those regions. Uncertain regulations challenging the sales of
patented pharmaceutical products has been a major deterring factor for global pharmaceutical
companies to enter into emerging economies. However, novel rugs for cancer type with no
treatment available currently would find positive outlook in these regions, though the high pricing
would inhibit their sales in emerging economies.
Global Key Players: